Mersana Therapeutics Inc (MRSN) Stock Analysis

Mersana Therapeutics Inc (MRSN) is a publicly traded company in the HEALTHCARE sector. It trades at $29.08. This page summarizes the public market data, fundamentals, and frequently asked questions for MRSN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About Mersana Therapeutics Inc

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to pioneering innovative Antibody Drug Conjugates (ADCs) to meet significant unmet needs in oncology. The company is advancing a strong pipeline of proprietary ADCs designed to enhance targeted therapy efficacy and improve patient outcomes. With a commitment to transforming cancer treatment, Mersana continues to progress through pivotal clinical trials and collaborates...

GNG Research Analysis

GNG Research scores Mersana Therapeutics Inc (MRSN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MRSN.

Frequently Asked Questions

Does MRSN pay dividends?

Mersana Therapeutics Inc (MRSN) does not currently pay a regular dividend.